3,409 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by North Dakota State Investment Board

North Dakota State Investment Board acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,409 shares of the company’s stock, valued at approximately $483,000.

Other large investors have also added to or reduced their stakes in the company. AlTi Global Inc. boosted its position in Neurocrine Biosciences by 1.0% during the third quarter. AlTi Global Inc. now owns 6,828 shares of the company’s stock worth $959,000 after purchasing an additional 70 shares during the period. Vanguard Personalized Indexing Management LLC boosted its position in Neurocrine Biosciences by 0.7% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 11,112 shares of the company’s stock worth $1,560,000 after purchasing an additional 77 shares during the period. Perigon Wealth Management LLC boosted its position in Neurocrine Biosciences by 3.1% during the fourth quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company’s stock worth $367,000 after purchasing an additional 78 shares during the period. Signaturefd LLC boosted its position in Neurocrine Biosciences by 4.5% during the fourth quarter. Signaturefd LLC now owns 1,925 shares of the company’s stock worth $273,000 after purchasing an additional 83 shares during the period. Finally, Great Lakes Advisors LLC boosted its position in Neurocrine Biosciences by 2.4% during the third quarter. Great Lakes Advisors LLC now owns 3,605 shares of the company’s stock worth $506,000 after purchasing an additional 84 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Up 0.8%

NBIX stock opened at $156.70 on Friday. The firm has a 50 day moving average of $136.68 and a 200-day moving average of $138.90. Neurocrine Biosciences, Inc. has a 12 month low of $117.59 and a 12 month high of $162.39. The firm has a market capitalization of $15.76 billion, a P/E ratio of 24.14, a price-to-earnings-growth ratio of 1.17 and a beta of 0.34.

Insider Activity

In other news, Director Leslie V. Norwalk sold 3,810 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $155.01, for a total value of $590,588.10. Following the completion of the transaction, the director directly owned 2,429 shares in the company, valued at approximately $376,519.29. This trade represents a 61.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard F. Pops sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $157.65, for a total transaction of $2,364,750.00. Following the completion of the transaction, the director owned 34,480 shares of the company’s stock, valued at $5,435,772. This trade represents a 30.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 263,898 shares of company stock worth $40,779,769. 4.60% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on NBIX shares. UBS Group cut their target price on shares of Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Wall Street Zen upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 25th. Zacks Research upgraded shares of Neurocrine Biosciences from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 15th. Piper Sandler increased their target price on shares of Neurocrine Biosciences from $190.00 to $207.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Finally, Royal Bank Of Canada increased their target price on shares of Neurocrine Biosciences from $176.00 to $180.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $185.90.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.